First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine March 31, 2023
Dose Escalation Portion of Phase 1 Solid Tumors Trial of TRE-515 Produces Favorable Results in Heavily Pretreated Solid Tumor Patients March 31, 2023
Volastra Therapeutics in-licenses Clinical Stage KIF18A Inhibitor And Secures $60 Million in Series A Funding To Further Advance Cancer-Focused Pipeline March 15, 2023
Tachyon Receives Funding from CIRM for a Ph 1 Study of TACH101 in Patients with Advanced Solid Tumors March 15, 2023
Enhertu Showed Clinically Meaningful and Durable Responses Across Multiple HER2-Expressing Tumour Types in DESTINY-PanTumor02 Ph 2 Trial March 15, 2023
Kinnate Biopharma Acquires Ownership Stake from Kinnjiu Biopharma; Initiates Ph 1 Trial for Exarafenib (KIN-2787) in China February 28, 2023
Cullinan Oncology enters into an exclusive license with Harbour BioMed for the development and commercial rights of HBM7008 (CLN-418) in the U.S. February 22, 2023
Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors February 22, 2023
Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination February 22, 2023
MD Anderson and KKR-backed Replay form new product company Syena to pioneer first-in-class TCR NK cell therapy February 22, 2023
Nectin Therapeutics and Merck to test Anti-PVR Antibody NTX1088 + KEYTRUDA® in Patients with Locally Advanced and Metastatic Solid Tumors February 22, 2023
Dragonfly Therapeutics Announces All Rights Revert to Dragonfly for DF6002, its Proprietary IL12 Investigational Immunotherapy Program February 22, 2023
THIO + Atezolizumab or Pembrolizumab demonstrated Significantly Greater Tumor Inhibition February 22, 2023
Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Gen Anti-MUC1-C Agents for Drug-Resistant Cancers February 8, 2023
Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment February 8, 2023
Teon Therapeutics Announces Clinical Trial Collaboration With Merck to Evaluate TT-81 in Combination with KEYTRUDA February 1, 2023
TC BioPharm and The University of Texas MD Anderson Cancer Center Announce Strategic Collaboration to Advance Gamma Delta T Cells in Oncology February 1, 2023
First Patient dosed in Ph I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors February 1, 2023
FDA Clears IND Application for Ph 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors February 1, 2023
